# Long-Term Study of EN3835 (CCH-aaes) in Edematous Fibrosclerotic Panniculopathy (Cellulite)

> **NCT03526549** · PHASE3 · COMPLETED · sponsor: **Endo Pharmaceuticals** · enrollment: 483 (actual)

## Conditions studied

- Edematous Fibrosclerotic Panniculopathy
- Cellulite

## Interventions

- **BIOLOGICAL:** CCH-aaes
- **OTHER:** Observation

## Key facts

- **NCT ID:** NCT03526549
- **Lead sponsor:** Endo Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-04-26
- **Primary completion:** 2021-10-08
- **Final completion:** 2021-10-08
- **Target enrollment:** 483 (ACTUAL)
- **Last updated:** 2023-09-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03526549

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03526549, "Long-Term Study of EN3835 (CCH-aaes) in Edematous Fibrosclerotic Panniculopathy (Cellulite)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03526549. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*